Form 4: Solenos CBO Kevin Norrett Reports Equity Grant

Solenos Therapeutics Chief Business Officer Kevin Norrett reported the acquisition of restricted stock units and employee stock options.

Summary

• Kevin Norrett, Chief Business Officer of Soleno Therapeutics Inc. (SLNO), reported changes in his beneficial ownership.
• Acquired 3,500 Restricted Stock Units (RSUs) on January 21, 2026, with a price of $0 per unit.
• These 3,500 RSUs will vest 100% on December 15, 2027, contingent on continued service as a Service Provider.
• Beneficially owns a total of 17,786 RSUs after this reported transaction, subject to their respective vesting schedules.
• Acquired 4,000 employee stock options on January 21, 2026, with an exercise price of $43.65 per share.
• These options begin vesting on February 1, 2026, with 1/48th of the shares vesting monthly thereafter, subject to continued service.
• The employee stock options have an expiration date of January 21, 2036.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation for a key executive, which is generally positive for aligning interests and retention, but does not contain information that would significantly alter the company's fundamental outlook or financial performance in the short term.

Positives

• Increased equity ownership for a key executive, Kevin Norrett, aligning his interests with long-term shareholder value.
• Long-term vesting schedules for both the 3,500 RSUs (vesting December 15, 2027) and 4,000 stock options (monthly vesting over 48 months) incentivize continued service and performance.

Negatives

• No immediate cash value realized from these grants, as they are subject to future vesting conditions and market performance.

Risks

• Vesting of both the RSUs and stock options is contingent on Kevin Norrett continuing to be a Service Provider, meaning forfeiture if employment ceases before vesting dates.
• The value of the stock options is dependent on the future stock price exceeding the exercise price of $43.65 per share.

Future Outlook

The equity grants, with their multi-year vesting schedules, indicate an expectation of continued service from the Chief Business Officer and a long-term commitment to the company's performance and strategic objectives.

Industry Context

Equity grants to key executives are a standard practice in the biotechnology and pharmaceutical industry, particularly for companies like Soleno Therapeutics, which are often in development stages. These grants are crucial for attracting and retaining talent, aligning executive incentives with long-term shareholder value creation, and compensating for potential lower cash salaries compared to larger, more established firms.

Comparison to Industry Standards

• The structure of these equity grants, including a mix of RSUs and stock options with multi-year vesting, is consistent with typical executive compensation packages in the biotech sector.
• Such grants are common across peers in the clinical-stage or commercial-stage biopharmaceutical space, aiming to retain talent and incentivize performance over several years.
• The exercise price of $43.65 for the options reflects the stock price at the time of grant, which is a standard practice for employee stock options.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with long-term shareholder value through equity ownership. Potential for future dilution from share issuance upon vesting/exercise, which is standard for equity compensation.
• Employees: Reinforces the company's commitment to retaining key talent through competitive compensation packages.

Next Steps

• Continued vesting of 1/48th of the employee stock options monthly starting February 1, 2026.
• Vesting of 100% of the 3,500 RSUs on December 15, 2027, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation grants to a key executive, the Chief Business Officer. While these grants align executive incentives with long-term shareholder value and aid in retention, they do not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The grants are a standard part of executive compensation and do not inherently signal a 'buy' or 'sell' opportunity based solely on this filing.

Keywords

SOLENO THERAPEUTICS, SLNO, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Executive Compensation, Kevin Norrett